CTLA4 and hypopituitarism: Some agent-specific associations have been demonstrated in the literature, with hypopituitarism mostly seen following anti-CTLA-4 treatment and thyroid dysfunction being correlated with anti-PD-1 and anti-PD-L1 antibodies [24].